Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) for the quarter ending January 31, 2024: -0.31

Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) is -0.31 for the quarter ending January 31, 2024, a -518.00% change year over year. The cash return on equity ratio measures the profitability of a company's shareholders' equity based on its operating cash flow. It is calculated by dividing operating cash flow by shareholders' equity. This ratio provides insight into how effectively the company generates cash flow in relation to the shareholders' investment. A higher ratio indicates better cash flow generation relative to the equity invested.

Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) for the quarter ending January 31, 2023 was -0.05, a 25.54% change year over year.
Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) for the quarter ending January 31, 2022 was -0.07, a 47.78% change year over year.
Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) for the quarter ending January 31, 2021 was -0.13, a 11.32% change year over year.
Kalvista Pharmaceuticals Inc Cash Return on Equity (CROE) for the quarter ending January 31, 2020 was -0.15, a -39.98% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends